Cargando…

Immunotherapy earns its spot in the ranks of cancer therapy

Since it became clear that all cancer cells express tumor-specific and tumor-selective antigens generated by genetic alterations and epigenetic dysregulation, the immunology community has embraced the possibility of designing therapies to induce targeted antitumor immune responses. The potential the...

Descripción completa

Detalles Bibliográficos
Autores principales: Pardoll, Drew, Drake, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280881/
https://www.ncbi.nlm.nih.gov/pubmed/22330682
http://dx.doi.org/10.1084/jem.20112275
_version_ 1782223878834094080
author Pardoll, Drew
Drake, Charles
author_facet Pardoll, Drew
Drake, Charles
author_sort Pardoll, Drew
collection PubMed
description Since it became clear that all cancer cells express tumor-specific and tumor-selective antigens generated by genetic alterations and epigenetic dysregulation, the immunology community has embraced the possibility of designing therapies to induce targeted antitumor immune responses. The potential therapeutic specificity and efficacy of such treatments are obvious to anyone who studies the exquisite specificity and cytocidal potency of immune responses. However, the value assigned to a therapeutic modality by the oncology community at large does not depend on scientific principle; all that matters is how patients respond. The bar for the ultimate acceptance of a therapy requires more than anecdotal clinical responses; rather, the major modalities of cancer therapeutics, including surgery, chemotherapy, radiation therapy, and, more recently, drugs targeting oncogenes, have earned their place only after producing dramatic frequent clinical responses or demonstrating statistically significant survival benefits in large randomized phase 3 clinical trials, leading to FDA approval. Although tumor-targeted antibodies have certainly cleared this bar, immunotherapies aimed at harnessing antitumor cellular responses have not—until now.
format Online
Article
Text
id pubmed-3280881
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-32808812012-08-13 Immunotherapy earns its spot in the ranks of cancer therapy Pardoll, Drew Drake, Charles J Exp Med Perspective Since it became clear that all cancer cells express tumor-specific and tumor-selective antigens generated by genetic alterations and epigenetic dysregulation, the immunology community has embraced the possibility of designing therapies to induce targeted antitumor immune responses. The potential therapeutic specificity and efficacy of such treatments are obvious to anyone who studies the exquisite specificity and cytocidal potency of immune responses. However, the value assigned to a therapeutic modality by the oncology community at large does not depend on scientific principle; all that matters is how patients respond. The bar for the ultimate acceptance of a therapy requires more than anecdotal clinical responses; rather, the major modalities of cancer therapeutics, including surgery, chemotherapy, radiation therapy, and, more recently, drugs targeting oncogenes, have earned their place only after producing dramatic frequent clinical responses or demonstrating statistically significant survival benefits in large randomized phase 3 clinical trials, leading to FDA approval. Although tumor-targeted antibodies have certainly cleared this bar, immunotherapies aimed at harnessing antitumor cellular responses have not—until now. The Rockefeller University Press 2012-02-13 /pmc/articles/PMC3280881/ /pubmed/22330682 http://dx.doi.org/10.1084/jem.20112275 Text en © 2012 Pardoll and Drake This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
spellingShingle Perspective
Pardoll, Drew
Drake, Charles
Immunotherapy earns its spot in the ranks of cancer therapy
title Immunotherapy earns its spot in the ranks of cancer therapy
title_full Immunotherapy earns its spot in the ranks of cancer therapy
title_fullStr Immunotherapy earns its spot in the ranks of cancer therapy
title_full_unstemmed Immunotherapy earns its spot in the ranks of cancer therapy
title_short Immunotherapy earns its spot in the ranks of cancer therapy
title_sort immunotherapy earns its spot in the ranks of cancer therapy
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280881/
https://www.ncbi.nlm.nih.gov/pubmed/22330682
http://dx.doi.org/10.1084/jem.20112275
work_keys_str_mv AT pardolldrew immunotherapyearnsitsspotintheranksofcancertherapy
AT drakecharles immunotherapyearnsitsspotintheranksofcancertherapy